Please assess the completion status of the following clinical trial:

Trial Title: Induction With or Without Granulocyte Colony-Stimulating Factor in AML Transplantation in AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed AML~* Age over 16~* Performance status greater than 60~* Previously untreated~* Peripheral blood white blood cell (WBC) count of less than (\<) 0.5 x109/L, and/or marrow leukemic blasts\< 20 % at 7th day of remission induction treatment~Exclusion Criteria:~* Previously treated~* Acute promyelocytic leukemia~* Age equal or younger than 15

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- control (Type: NO_INTERVENTION): remission induction with cytosine arabinoside amd idarubicine
- G-CSF (Type: EXPERIMENTAL): G-CSF was administered starting on Day 8 until neutrophil recovery

Based on this trial design, predict the completion outcome and termination type (if applicable).